Stifel lowered its price target for Alphatec Holdings (NASDAQ: ATEC) to $13 from $16. The firm maintained a Buy rating on the medical technology stock.
Analysts cited potential cuts to 2026 surgical revenue guidance as a primary concern. The adjustment follows a recent growth slowdown and challenging year-over-year comparisons in upcoming quarters.
Stifel remains confident in long-term prospects, specifically highlighting 2027 opportunities in the deformity market. The stock currently trades at a sub-10x adjusted EBITDA multiple.
The firm noted that expanding margins and a strong growth story support the valuation. However, analysts suggested a more opportune entry point may emerge in the near future.